Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 1
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW. Matthews AH, et al. Among authors: bruno xj. Blood Adv. 2022 Jul 12;6(13):3997-4005. doi: 10.1182/bloodadvances.2022007265. Blood Adv. 2022. PMID: 35507945 Free PMC article.
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW. Matthews AH, et al. Among authors: bruno xj. Am J Hematol. 2023 Aug;98(8):1254-1264. doi: 10.1002/ajh.26991. Epub 2023 Jun 19. Am J Hematol. 2023. PMID: 37334852 Free PMC article.
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. Among authors: bruno xj. J Hematol Oncol. 2022 Jul 16;15(1):96. doi: 10.1186/s13045-022-01316-1. J Hematol Oncol. 2022. PMID: 35842643 Free PMC article.
Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. Among authors: bruno xj. Blood Adv. 2023 Jan 10;7(1):88-91. doi: 10.1182/bloodadvances.2022008634. Blood Adv. 2023. PMID: 36269847 Free PMC article. No abstract available.
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV. Connor MP, et al. Among authors: bruno xj. Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2024.285275. Online ahead of print. Haematologica. 2024. PMID: 38634143 Free article.